Mark Verrill
- Oncology top 2%
- Cancer Treatment and Pharmacology 35
- HER2/EGFR in Cancer Research 26
- Cancer Research top 5%
- Breast Cancer Treatment Studies 36
-
- Chemotherapy-induced cardiotoxicity and mitigation 6
-
- Advanced Breast Cancer Therapies 11
- Sarcoma Diagnosis and Treatment 7
- Cancer-related cognitive impairment studies 5
-
- Monoclonal and Polyclonal Antibodies Research 5
- Co-authors
- Chris PlummerPeter CanneyAlison JonesVictoria CorneliusGill LevittL. A. SmithAlan V. BoddyPeter Barrett‐Lee
- Journals
- Journal of Clinical Oncology (11 papers)Annals of Oncology (10 papers)European Journal of Cancer (8 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Mark Verrill
81 papers receiving 2.4k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Oncology 1.3k
- Cancer Research 473
- Cardiology and Cardiovascular Medicine 705
- Pulmonary and Respiratory Medicine 648
- Radiology, Nuclear Medicine and Imaging 313
Countries citing papers authored by Mark Verrill
This map shows the geographic impact of Mark Verrill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Verrill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Verrill more than expected).
Fields of papers citing papers by Mark Verrill
This network shows the impact of papers produced by Mark Verrill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Verrill. The network helps show where Mark Verrill may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Verrill, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 7 | |
| 2 | 2022 | 3 | |
| 3 | 2022 | 11 | |
| 4 | 2021 | 3 | |
| 5 | 2020 | 4 | |
| 6 | 2017 | 1 | |
| 7 | 2016 | 1 | |
| 8 | 2016 | 13 | |
| 9 | 2016 | 6 | |
| 10 | 2014 | 30 | |
| 11 | 2013 | 5 | |
| 12 | 2011 | 25 | |
| 13 | 2011 | 30 | |
| 14 | 2009 | 147 | |
| 15 | Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer. | 2006 | 1 |
| 16 | 2006 | 39 | |
| 17 | 2005 | 31 | |
| 18 | 2003 | 6 | |
| 19 | 2002 | 9 | |
| 20 | 1997 | 39 |
About Mark Verrill
Mark Verrill is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Gastroenterology and Cardiology and Cardiovascular Medicine, having authored 85 papers that have together received 2.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (36 papers), Cancer Treatment and Pharmacology (35 papers), HER2/EGFR in Cancer Research (26 papers), Advanced Breast Cancer Therapies (11 papers), Sarcoma Diagnosis and Treatment (7 papers), Chemotherapy-induced cardiotoxicity and mitigation (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cancer-related cognitive impairment studies (5 papers). The work is most often cited by research in Oncology (1.3k citations), Cancer Research (473 citations), Cardiology and Cardiovascular Medicine (705 citations), Pulmonary and Respiratory Medicine (648 citations) and Radiology, Nuclear Medicine and Imaging (313 citations). Mark Verrill has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Chris Plummer, Peter Canney, Alison Jones, Victoria Cornelius, Gill Levitt, L. A. Smith, Alan V. Boddy, Peter Barrett‐Lee, David Jamieson and Andrew Wardley. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, British Journal of Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.